Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm

The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works.

Rebecca Robbins
Author: Rebecca Robbins

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *